50
Psoriasis Christopher Betts (PGY I)

Psoriasis -cb

Embed Size (px)

Citation preview

Page 1: Psoriasis -cb

Psoriasis

Christopher Betts (PGY I)

Page 2: Psoriasis -cb

What is Psoriasis?

• Papulosquamous proliferative skin condition that is generally chronic and inflammatory in nature and often associated with systemic manifestations.

• Characterized as erythematous scaly papules and plaques with additional involvement of the nails and joints; pustular and erythrodermic eruptions can occur.

• Contributed w/ trauma (Koebner’s phenomenon)

Page 3: Psoriasis -cb

Psoriasis: Epidemiology

• Affects about 2-3% of US adults • Prevalence ranges from 0.1% to 3% in various

populations• Prevalence equal in males and females• Onset commonly around the ages 15-30, but

also can occur at any age

Page 4: Psoriasis -cb

Psoriasis: Risk factors & Etiology• Immune-mediated disease with genetic predisposition

– Approximately 1/3rd of pts w/ psoriasis have a first-degree relative w/ psoriasis

• Many stressful physiologic and psychological events and environmental factors a/w onset and worsening of the condition

• Lesions tend to develop in areas of trauma (Koebner's phenomena)• Strep throat infection is an example of a trigger and exacerbating

factor• HIV infection (more seen as an exacerbating factor)• Other risk factors, but not shown to be clearly causative, include

smoking, obesity, and alcohol use

Page 5: Psoriasis -cb

Psoriasis: Clinical presentation• Holds much weight in diagnosis, but skin bx is definitive• Typically as a erythematous, scaly patch or plaque which can be

itchy or painful• A scale in psoriasis is typically white and thin and when removed,

leaves pinpoint foci of bleeding (Auspitz sign). • The plaques and micaceous scales are easily recognizable in light-

skinned pts but to a lesser degree in dark-skinned pts and more difficult to discern.

• 90% of patients present with well-defined round or oval plaques that differ in size and often coalesce and situated over the extensor surfaces of extremities, scalp, buttocks, and trunk (plaque psoriasis).

Page 6: Psoriasis -cb
Page 7: Psoriasis -cb

Psoriasis: Non-cutaneous involvement

• Psoriatic onchodystrophy seen in 80-90% of patients w/ psoriasis over the lifetime (fingernails > toenails) – Pitting (most common), – Subungual hyperkeratosis (abnl keratinization of

the distal nail bed; accumulation of scales under distal nail plate)

– Onycholysis (separation of nail from its bed).

Page 8: Psoriasis -cb

onycholysis

pitting

Subungual keratosis

Page 9: Psoriasis -cb

Psoriasis: Clinical presentation

Guttate psoriasis• More common in patients younger than 30 yo• Truncal distribution• Comprises 2% of psoriasis cases• 1- to 10-mm pink papules w/ fine scaling• Can present several weeks after a Grp A beta-

hemolytic strep URI.

Page 10: Psoriasis -cb
Page 11: Psoriasis -cb

Psoriasis: Atypical presentations

• Inverse psoriasis: less scaly; occurs in skin folds and flexor surfaces; distribution includes perineal, inframammary, axillary, inguinal, and intergluteal areas; contributed by heat, trauma, and infection

Page 12: Psoriasis -cb
Page 13: Psoriasis -cb

Psoriasis: Atypical presentations

• Erythrodermic psoriasis: widespread and generalized erythema and associated w/ systemic symptoms; may be slow and incidious in chronic psoriasis or eruptive and abrupt in pts w/ mild psoriasis.

Page 14: Psoriasis -cb
Page 15: Psoriasis -cb

Psoriasis: Atypical presentations

• Pustular psoriasis: pustules over palms and soles w/o plaque formation.

Page 16: Psoriasis -cb
Page 17: Psoriasis -cb

Psoriatic arthritis

• Prevalence ranges from 6-42% of pts w/ psoriasis; male to female ratio 1:1

• Seronegative inflammatory arthritis w/ various clinical presentations

• On average, develops 12 yrs after the onset of skin symptoms.

Page 18: Psoriasis -cb

Classification Criteria for Psoriatic ArthritisSpecificity of 98.7% and sensitivity of 91.4%

Page 19: Psoriasis -cb

Psoriasis: Comorbid conditions• Association based on either pathophysiology, shared risk factors, or adverse

effects from treatments• Significant social morbidity• One survey conducted on patients w/ diagnosed psoriasis, 79% of them

thought that the disease negatively affected their lives by causing problems w/ work, activities of daily living, and socialization.

• Social isolation may contribute to incr risk of medical conditions that are mediated and prevented by exercise and lifestyle modifying practices.

• Incr disease severity a/w lower income, higher number of consultations w/ multiple physicians, and reduced satisfaction w/ treatment.

• Younger and female patients are most affected by psoriasis.• One survey found that more than one half of patients w/ severe psoriasis

thought physicians could do more to help, and 78% reported frustration w/ the effectiveness of treatment.

Page 20: Psoriasis -cb

Psoriasis: Comorbid conditions

Page 21: Psoriasis -cb

Psoriasis: Management

Page 22: Psoriasis -cb

Psoriasis: Management – overview

• Treatment goals include improvement of skin, nail, and joint lesions plus enhanced quality of life.

• Based on level of severity – in this case amt of BSA covered

• … and how systemic the condition is– Skin only vs. Skin + joint +/- other extra-dermal sites

• Major modalities of Tx: topical, phototherapy, systemic/biologic agents

• Management of compound co-morbidities (previous slide)

Page 23: Psoriasis -cb

Psoriasis: Management – overview

• Severity: Mild/moderate or Severe

– Mild/Moderate is <5% BSA affected• Genitals, hands, feet, face usually spared

– Severe is 5% or greater of BSA affected

Page 24: Psoriasis -cb

Psoriasis: Management – overview

• If Mild/Moderate, is the patient needing prn therapy or continuous therapy?– PRN/intermittent therapy: • Topical corticosteroids, • Vitamin D analogs, • Tazarotene (Tazorac) (SORT A)

– Continuous therapy: Calcineurin inhibitors• Tacrolimus, Pimecrolimus

Page 25: Psoriasis -cb

Psoriasis: Management – overview

• If Severe, is the BSA affected greater or less than 20%?– <20% BSA affected calls for Vitamin D analogs w/

phototherapy– >20% BSA affected calls for more systemic therapy

w/ phototherapy (SORT A)• Systemic tx: Methotrexate, Acitretin, Cyclosporine

– Any arthritic involvement calls for biologic therapy (not necessarily the same as systemic tx)• Adalimumab, Infliximab, Etanercept (SORT A)

Page 26: Psoriasis -cb

Psoriasis: Topical Tx’s in general• Ointment vs. cream vs. gel vs. lotion?? • Level of penetration: Lotion, gel < cream < ointment• The choice of formulation depends on area to cover, examples:

– Lotion for scalp– Cream for moist weeping lesions– Ointment for dry, lichenified, scaly lesions

• Emollients are ointments or thick creams that are used to reduce scaling and irritation.

• Ointment emollient example is Aquaphore• Thick cream emollient examples include Cerave, Nivea, Eucerin• Overall, individualized and based on a personal preference, level of

compliance, and dermatologic factors like skin type and plaque thickness.• Twice daily application

Page 27: Psoriasis -cb

Psoriasis: Topical Corticosteroids

• These, combined with emollients, are the most common and effective treatment to limited plaque psoriasis.

• Anti-inflammatory, ant proliferative, and immunosuppressive effects

• Twice daily application• The greater the potency the greater the improvement

in symptoms, based on systematic reviews• Common localized adverse effects are poor wound

healing, skin atropy, and irritation.

Page 28: Psoriasis -cb

Psoriasis: Topical Corticosteroids• Extended use of high potency steroids, although topical, can bring

about systemic effects similar to those from oral steroid use.• Children have a high ratio of BSA to weight, hence are most

vulnerable to adverse effects of steroid use in general. • Once symptoms improve, recommend to taper.• Tachyphylaxis of topical steroids is not uncommon and is either

related to genuine tolerance to long-term treatment or low adherence.

• Expense: a 60 g tube can be as high as $80. Foam and spray forms are new-type of formulations for better adherence but are also expensive. Generic forms available are shown below.

Page 29: Psoriasis -cb

Psoriasis: Topical Corticosteroids• US-graded potency scale ranges

– Grade I (most potent) to VII (least potent)• Some are the same name in different classes but varied in

potency based on formulations – Betamethasone: ointment (I) > cream (II) > lotion (III)

• The more sensitive or thinner the skin (i.e. face, intertrigous areas) the lower the potency called for (grades VI-VII)

• The thicker and angrier the lesion in areas of thicker skin (i.e. extremities) the higher the potency called for (grades I-III)

• Can be used in sequence for tapering effect.

Page 30: Psoriasis -cb
Page 31: Psoriasis -cb
Page 32: Psoriasis -cb
Page 33: Psoriasis -cb
Page 34: Psoriasis -cb
Page 35: Psoriasis -cb

Psoriasis: Topical CorticosteroidsMost commonly used ones for psoriatic plaques

– Hydrocortisone topical 2.5% (VII)– Triamcinolone topical 0.025% and 0.1% (IV and VI)– Fluocinonide topical 0.05% (II to III)– Halobetasol topical 0.05% (I)– Betamethasone Diproprionate topical 0.05% - Grade I to V

Three-dollar list ones: – Betamethasone diproprionate 0.05% cream (I,II), – Betamethasone valerate 0.01% cream (V) and ointment (III), – Fluocinolone soln 0.01% (VI), – Fluocinonide cream 0.05% (II), – Hydrocortisone cream 1% and 2.5% (VI, VII), – Triamcinolone cream 0.025% (VI), 0.1% (IV), 0.5% (III), – Triamcinolone 0.1% ointment (III)

Page 36: Psoriasis -cb

Psoriasis: Topical Vitamin D analogs

• Hypoproliferative effect on keratinocytes; questionable immunomodulating effect; inactivated by UVA light

• Monotherapy < combination therapy either w/ phototherapy or topical steroid; combined emollient use also common

• Slower onset of action (6-8 wks) but longer disease-free interval than topical steroids

• Adverse effects: hypercalcemia, PTH suppression– High risk: pts w/ supratherapeutic doses and those w/ renal

insufficiency

Page 37: Psoriasis -cb

Psoriasis: Topical Vitamin D analogs

• Calcipotriene (Dovonex) 0.005% ($)– Twice a day application; generic form as well– Available in all types of formulations

• Calcitriol (Vectical) – 3 mcg/g ($$)– Only in ointment form; originally was available only in Europe;

demonstrated in one systematic review study to have less skin irritative effects compared to calcipotriene

– One 52-wk open labeled study in 2009 demonstrated less hypercalcemic adverse effects

• Both are well tolerated agents; safe for pediatric use; both are expensive

Page 38: Psoriasis -cb

Psoriasis: Topical Vitamin D analogs

• Combination Vit D + topical steroids available but very expensive– Calcipotriene + Betamethasone diproprionate

0.064% (Talconex) = $400 for 60g tube

Page 39: Psoriasis -cb

Psoriasis: Tazarotene• Chemically related to Vitamin A; regulate epithelial growth• Topical retinoid 0.1% and 0.05%: cream, foam, gel (pediatric use)• Two RVCT double-blind study (Amer J of Derm, 2003) of 1303 pts w/

psoriasis using 0.1% and 0.05% creams qd for 12 weeks: – Significant reductions in severity of clinical signs of psoriasis– Therapeutic effect maintained during post-treatment period

(unspecified duration)– 0.1% cream w/ more skin irritative effects than 0.05% cream

• As effective as potent topical corticosteroids in alleviating symptoms of psoriasis and a/w longer disease-free intervals

• Approved for psoriasis in patients older than 18 yo and tx of acne in pts > 12 yo

Page 40: Psoriasis -cb

Psoriasis: Tazarotene

• Adverse effect: perilesional itching and burning (common); teratogenic

• Regimen of alternating days w/ topical corticosteroid and moisturizers

• One multicentre, non-controlled study in 2006 studying short-term tazarotene therapy in 43 pts w/ psoriasis vulgaris– Results showed that short-term treatment (20 min of

application followed by washing) was just as effective as traditional treatment

Page 41: Psoriasis -cb

Psoriasis: Calcineurin inhibitors• Tacrolimus > Pimecrolimus• From two RCTs in 2004: Effective in facial and intertriginous

psoriasis• Approved for use in patients > 2 yo • FDA approved?: Mainly approved for therapy for mod-severe

atopic dermatitis.• A considered alternative to chronic topical steroid use over

sensitive areas• Improve symptoms w/ less skin atrophy than topical

corticosteroids• Boxed warning: skin malignancy and lymphoma (FDA report 2005)

Page 42: Psoriasis -cb

Psoriasis: Calcineurin inhibitors

• In 2004, 8 wk double-blind RVCT study of 167 pts >16 yo with intertriginous and facial psoriasis applying twice a day 0.1% tacrolimus ointment; results showed more patients achieving clearance of lesions or excellent improvement compared to placebo (65% to 32%)

• Second study in 2004, RVCT of 57 pts w/ mod-to-severe inverse psoriasis for 8 weeks of bid usage pimecrolimus: 1% cream is an effective tx for inverse psoriasis w/ rapid onset of action, safe, well-tolerated

Page 43: Psoriasis -cb

Psoriasis: Phototherapy

• Mainly for refractory and/or severe psoriasis

Page 44: Psoriasis -cb

Psoriasis: Systemic therapiesMethotrexate• MTX used for patients of severe psoriasis (BSA >5%)• used to treat psoriatic disease for >50 yrs• Administered weeklyCyclosporine• Rapid alleviation of symptoms• multiple adverse effects and drug interactions preclude long-term

use• often used for suppressing crises and as bridge therapy during

initiation of slower-onset maintanence therapies.• Both MTX and cyclosporine are not approved for treating severe

psoriasis in children

Page 45: Psoriasis -cb

Psoriasis: Systemic therapies

Acitretin• Oral retinoid w/ slow onset of effect (up to 6

mo)• teratogenic, causes mucocutaneous lesions,

hyperlipidemia, and elevated LFTs• more effective when combined w/

phototherapy.

Page 46: Psoriasis -cb

Psoriasis: Biologic therapy• Increasingly used in treating moderate-to-severe psoriasis

and in psoriatic arthritis• Tumor necrosis factor inhibitors (Humira, Enbrel, Remicade)• Etanercept (Enbrel) commonly combined w/ MTX for

effective use.• Infliximab (Remicade) reported in clinical trials to have the

most rapid and sustained response• Risk of infection: Usage of any TNF inhibitor contrainidcates

for live vaccine usage and calls for a baseline PPD tuberculin skin test.

Page 47: Psoriasis -cb

Psoriasis: Management

Page 48: Psoriasis -cb

Psoriasis: Management

Page 49: Psoriasis -cb
Page 50: Psoriasis -cb

Questions and critics welcomed…

Resources:• AAFP article: Psoriasis (May 2013)• http://www.psoriasis.org/• http://www.guideline.gov/content.aspx?id=12

505• Medscape Reference, Up To Date, Epocrates

online